Keywords: phase, i/ii, data, gilead, pmpa, 20-patient, study
Phase I/II Data With Gilead's PMPA
Article | 21 April 1997
- Data from a 20-patient, Phase I/II study in which Gilead Sciences'antiretroviral agent PMPA was administered intravenously as a monotherapy, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
